Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL27443089 | 0.98 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBLMNAALDH1A1HPGD | |
| SCHEMBL1859157 | 0.96 | SMN1; SMN2 (0.69) | SMN1; SMN2POLBLMNAALDH1A1HPGD | |
| SCHEMBL30700617 | 0.94 | SMN1; SMN2 (0.62) | SMN1; SMN2POLBLMNAALDH1A1HPGD | |
| SCHEMBL1826048 | 0.94 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBLMNAALDH1A1HPGD | |
| SCHEMBL7838421 | 0.94 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBLMNAALDH1A1HPGD | |
| SCHEMBL11492059 | 0.94 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBLMNAALDH1A1HPGD | |
| SCHEMBL9405372 | 0.92 | POLB (0.73) | SMN1; SMN2POLBLMNAALDH1A1HPGD | |
| SCHEMBL5405182 | 0.90 | SMN1; SMN2 (0.62) | SMN1; SMN2POLBLMNAALDH1A1HPGD | |
| SCHEMBL5935756 | 0.89 | LMNA (0.60) | SMN1; SMN2POLBLMNAMEN1KMT2A | |
| SCHEMBL19830587 | 0.89 | LMNA (0.60) | SMN1; SMN2POLBLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | claimed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | claimed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | claimed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115244037-A | Substituted triazinones as thyroid hormone receptor agonists | 上海诚益生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115135636-A | Quinoxalinone derivatives as irreversible inhibitors of KRAS G12C mutant proteins | 北京泰德制药股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114945571-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-102812026-A | Oral carbapenem compounds containing aminosulfonyl azetidinyl | SHANDONG XUANZHU PHARM TECH CO | 2012-12-05 | — | — | CN | disclosed |
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | SMN1; SMN2 4066/4885POLB 3563/4885LMNA 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.